With these findings in mind, PGD2 and its receptor CRTH2 has become one of the most promising therapeutic targets in the field of allergy and asthma, which was also fueled by the discovery of indomethacin as a potent and selective CRTH2 agonist. This evidence concerns the gene PTGDR2 and allergic disease.